Circulation Research,
Год журнала:
2024,
Номер
135(1), С. 198 - 221
Опубликована: Июнь 20, 2024
From
their
humble
discovery
as
cellular
debris
to
cementing
natural
capacity
transfer
functional
molecules
between
cells,
the
long-winded
journey
of
extracellular
vesicles
(EVs)
now
stands
at
precipice
a
next-generation
cell-free
therapeutic
tool
revolutionize
modern-day
medicine.
This
perspective
provides
snapshot
EVs
emergence
vibrant
field
biology
and
renaissance
they
usher
in
biomedical
sciences
agents
for
cardiovascular
pathologies.
Rapid
development
bioengineered
is
providing
innovative
opportunities
overcome
biological
challenges
such
potency,
cargo
loading
enhanced
secretion,
targeting
circulation
half-life,
localized
sustained
delivery
strategies,
approaches
enhance
systemic
circulation,
uptake
lysosomal
escape,
logistical
hurdles
encompassing
scalability,
cost,
time.
A
multidisciplinary
collaboration
beyond
extends
chemistry,
physics,
biomaterials,
nanotechnology,
allowing
rapid
designer
that
are
entering
late-stage
human
clinical
trials.
Molecular Therapy,
Год журнала:
2023,
Номер
31(5), С. 1231 - 1250
Опубликована: Фев. 20, 2023
Extracellular
vesicles
(EVs)
are
gaining
increasing
attention
for
diagnostic
and
therapeutic
applications
in
various
diseases.
These
natural
nanoparticles
benefit
from
favorable
safety
profiles
unique
biodistribution
capabilities,
rendering
them
attractive
drug-delivery
modalities
over
synthetic
analogs.
However,
the
widespread
use
of
EVs
is
limited
by
technological
shortcomings
biological
knowledge
gaps
that
fail
to
unravel
their
heterogeneity.
An
in-depth
understanding
biogenesis
crucial
unlocking
full
potential.
Here,
we
explore
how
about
EV
can
be
exploited
bioengineering
load
protein
or
nucleic
acid
cargos
into
onto
EVs.
We
summarize
more
than
75
articles
discuss
findings
on
formation
composition
exosomes
microvesicles,
revealing
multiple
pathways
may
stimulation
and/or
cargo
dependent.
Our
analysis
further
identifies
key
regulators
loading
this
integrated
develop
engineered
biotherapeutics.
Journal of Nanobiotechnology,
Год журнала:
2023,
Номер
21(1)
Опубликована: Июль 20, 2023
Abstract
Extracellular
vesicles
(EVs)
are
nano-sized,
natural,
cell-derived
that
contain
the
same
nucleic
acids,
proteins,
and
lipids
as
their
source
cells.
Thus,
they
can
serve
natural
carriers
for
therapeutic
agents
drugs,
have
many
advantages
over
conventional
nanocarriers,
including
low
immunogenicity,
good
biocompatibility,
blood
–
brain
barrier
penetration,
capacity
gene
delivery.
This
review
first
introduces
classification
of
EVs
then
discusses
several
currently
popular
methods
isolating
purifying
EVs,
EVs-mediated
drug
delivery,
functionalization
carriers.
Thereby,
it
provides
new
avenues
development
EVs-based
strategies
in
different
fields
medicine.
Finally,
highlights
some
challenges
future
perspectives
with
regard
to
clinical
application
EVs.
Graphical
Acta Pharmaceutica Sinica B,
Год журнала:
2023,
Номер
13(11), С. 4391 - 4416
Опубликована: Май 20, 2023
Owing
to
the
inherent
shortcomings
of
traditional
therapeutic
drugs
in
terms
inadequate
efficacy
and
toxicity
clinical
treatment,
nanomedicine
designs
have
received
widespread
attention
with
significantly
improved
reduced
non-target
side
effects.
Nanomedicines
hold
tremendous
theranostic
potential
for
treating,
monitoring,
diagnosing,
controlling
various
diseases
are
attracting
an
unfathomable
amount
input
research
resources.
Against
backdrop
exponentially
growing
number
publications,
it
is
imperative
help
audience
get
a
panorama
image
activities
field
nanomedicines.
Herein,
this
review
elaborates
on
development
trends
nanomedicines,
emerging
nanocarriers,
vivo
fate
safety
their
extensive
applications.
Moreover,
challenges
obstacles
hindering
translation
nanomedicines
also
discussed.
The
elaboration
aspects
may
enlighten
readers
set
route
future
endeavors.
Bioactive Materials,
Год журнала:
2023,
Номер
27, С. 1 - 14
Опубликована: Март 23, 2023
Intracerebral
hemorrhage
(ICH),
as
a
type
of
life-threatening
and
highly
disabled
disease,
has
limited
therapeutic
approaches.
Here,
we
show
that
exosomes
derived
from
young
healthy
human
plasma
exhibiting
typical
features
could
facilitate
functional
recovery
ICH
mice.
When
these
are
intraventricularly
delivered
into
the
brain
after
ICH,
they
mainly
distribute
around
hematoma
be
internalized
by
neuronal
cells.
Strikingly,
administration
markedly
enhanced
behavioral
mice
through
reducing
injury
cell
ferroptosis.
MiRNA
sequencing
revealed
microRNA-25-3p
(miR-25-3p)
was
differentially
expressed
miRNA
in
plasma,
compared
with
old
control.
Importantly,
miR-25-3p
mimicked
treatment
effect
on
improvement,
mediated
neuroprotective
against
ferroptosis
ICH.
Furthermore,
luciferase
assay
western
blotting
data
illustrated
P53
assumed
role
downstream
effector
miR-25-3p,
thereby
regulating
SLC7A11/GPX4
pathway
to
counteract
Taken
together,
findings
firstly
reveal
improve
counteracting
ferroptotic
P53/SLC7A11/GPX4
axis
Given
easy
availability
exosomes,
our
study
provides
potent
strategy
for
patients
quick
clinical
translation
near
future.
Journal of Nanobiotechnology,
Год журнала:
2023,
Номер
21(1)
Опубликована: Июль 12, 2023
Abstract
Apoptosis,
a
form
of
programmed
cell
death,
is
essential
for
growth
and
tissue
homeostasis.
Apoptotic
bodies
(ApoBDs)
are
extracellular
vesicles
(EVs)
released
by
dying
cells
in
the
last
stage
apoptosis
were
previously
regarded
as
debris
dead
cells.
Recent
studies
unraveled
that
ApoBDs
not
but
bioactive
treasure
left
behind
with
an
important
role
intercellular
communications
related
to
human
health
various
diseases.
Defective
clearance
infected-cells-derived
possible
etiology
some
Therefore,
it
necessary
explore
function
mechanism
action
different
physiological
pathological
conditions.
advances
have
elucidated
immunomodulatory,
virus
removal,
vascular
protection,
regenerative,
disease
diagnostic
potential
ApoBDs.
Moreover,
can
be
used
drug
carriers
enhancing
stability,
cellular
uptake,
targeted
therapy
efficacy.
These
reports
from
literature
indicate
hold
promising
diagnosis,
prognosis,
treatment
diseases,
including
cancer,
systemic
inflammatory
cardiovascular
regeneration.
This
review
summarizes
recent
ApoBDs-related
research
discusses
diseases
well
challenges
prospects
ApoBDs-based
therapeutic
applications.
Graphical
Proceedings of the National Academy of Sciences,
Год журнала:
2023,
Номер
120(28)
Опубликована: Июль 3, 2023
Exosomes
(EXOs)
have
been
proven
as
biomarkers
for
disease
diagnosis
and
agents
therapeutics.
Great
challenge
remains
in
the
separation
of
EXOs
with
high-purity
low-damage
from
complex
biological
media,
which
is
critical
downstream
applications.
Herein,
we
report
a
DNA-based
hydrogel
to
realize
specific
nondestructive
media.
The
separated
were
directly
utilized
detection
human
breast
cancer
clinical
samples,
well
applied
therapeutics
myocardial
infarction
rat
models.
materials
chemistry
basis
this
strategy
involved
synthesis
ultralong
DNA
chains
via
an
enzymatic
amplification,
formation
hydrogels
through
complementary
base-pairing.
These
that
contained
polyvalent
aptamers
able
recognize
bind
receptors
on
EXOs,
efficient
binding
ensured
selective
media
into
further
formed
networked
hydrogel.
Based
hydrogel,
rationally
designed
optical
modules
introduced
exosomal
pathogenic
microRNA,
achieved
classification
patients
versus
healthy
donors
100%
precision.
Furthermore,
mesenchymal
stem
cell–derived
was
proved
significant
therapeutic
efficacy
repairing
infarcted
myocardium
We
envision
hydrogel–based
bioseparation
system
promising
powerful
biotechnology,
will
promote
development
extracellular
vesicles
nanobiomedicine.
Nature Communications,
Год журнала:
2023,
Номер
14(1)
Опубликована: Июль 7, 2023
Abstract
The
transplantation
of
mesenchymal
stem
cells-derived
secretome,
particularly
extracellular
vesicles
is
a
promising
therapy
to
suppress
spinal
cord
injury-triggered
neuroinflammation.
However,
efficient
delivery
the
injured
cord,
with
minimal
damage,
remains
challenge.
Here
we
present
device
for
treat
injury.
We
show
that
incorporating
cells
and
porous
microneedles
enables
vesicles.
demonstrate
topical
application
lesion
beneath
dura,
does
not
damage
lesion.
evaluate
efficacy
our
in
contusive
injury
model
find
it
reduces
cavity
scar
tissue
formation,
promotes
angiogenesis,
improves
survival
nearby
tissues
axons.
Importantly,
sustained
at
least
7
days
results
significant
functional
recovery.
Thus,
provides
an
platform
treatment.
